Advances strategy to partner seladelpar for PBC outside U.S.
Brings in approximately $34.0 million upfront payment
Japan represents an important market with no currently approved second line treatment
https://www.marketscreener.com/quote/stock/CYMABAY-THERAPEUTICS-INC-16725724/news/CymaBay-Therapeutics-Announces-Collaboration-with-Kaken-Pharmaceutical-Co-Ltd-to-Develop-and-Comm-42688123/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.